Expression and Purification of EPHA2 Tyrosine Kinase Domain for Crystallographic and NMR Studies.

about

Expression and Purification of EPHA2 Tyrosine Kinase Domain for Crystallographic and NMR Studies.

Item

http://www.wikidata.org/entity/Q41989875

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Expression and Purification of ...... stallographic and NMR Studies.

@en

type

Item

label

Expression and Purification of ...... stallographic and NMR Studies.

@en

prefLabel

Expression and Purification of ...... stallographic and NMR Studies.

@en

P1476

Expression and Purification of ...... stallographic and NMR Studies.

@en

P2093

Andreas J Reichert

http://www.w3.org/2001/XMLSchema#string

Bernhard Kuster

http://www.w3.org/2001/XMLSchema#string

Denis Kudlinzki

http://www.w3.org/2001/XMLSchema#string

Krishna Saxena

http://www.w3.org/2001/XMLSchema#string

Santosh L Gande

http://www.w3.org/2001/XMLSchema#string

Sridhar Sreeramulu

http://www.w3.org/2001/XMLSchema#string

Verena Linhard

http://www.w3.org/2001/XMLSchema#string

P2860

EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt

Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site

Structures of the cancer-related Aurora-A, FAK, and EphA2 protein kinases from nanovolume crystallography

The Eph family of receptors

Ectodomain structures of Eph receptors

The role of ephrins and Eph receptors in cancer

Phosphorylation of tyrosine residues in the kinase domain and juxtamembrane region regulates the biological and catalytic activities of Eph receptors

NMR screening and crystal quality of bacterially expressed prokaryotic and eukaryotic proteins in a structural genomics pipeline

25 years of small molecular weight kinase inhibitors: potentials and limitations.

Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis.

P304

2257-2263

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CBIC.201600483

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Harald Schwalbe

Stephanie Heinzlmeir

Arne Skerra

P577

2016-09-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27685543

http://www.w3.org/2001/XMLSchema#string